October 28, 2020, GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin (GSK2140944). Gepotidacin is the first in a new class of antibiotics, called triazaacenaphthylene topoisomerase inhibitors, developed at GSK in 2007 with a novel “dual targeting” mechanism of action (MOA) and oral formulation. Its MOA is distinct from any currently approved antibiotic. Fantastic news!
1 comment:
October 28, 2020, GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin (GSK2140944). Gepotidacin is the first in a new class of antibiotics, called triazaacenaphthylene topoisomerase inhibitors, developed at GSK in 2007 with a novel “dual targeting” mechanism of action (MOA) and oral formulation. Its MOA is distinct from any currently approved antibiotic. Fantastic news!
Post a Comment